<?xml version="1.0" encoding="UTF-8" ?>
			<?xml-stylesheet href="/rss/rss2html.xsl" type="text/xsl" media="screen"?>
			<rss version="2.0" xmlns:alacra="http://www.alacra.com" xmlns:spcred="http://www.alacra.com/spcred" xmlns:fitch="http://www.alacra.com/fitch" xmlns:newstex="http://www.alacra.com/newstex" ><channel><title>AstraZeneca plc RSS Research Feed - Subscribe Today - AlacraStore.com</title>
<description>AstraZeneca plc</description>
<link>http://www.alacrastore.com/company-snapshot/AstraZeneca_plc-1069149</link>
<lastBuildDate>Thursday, July 24, 2008 3:15:16 PM</lastBuildDate>
<alacra:xlsid>1069149</alacra:xlsid>
<alacra:company>AstraZeneca plc</alacra:company>
<language>en</language>
<generator>AlacraStore RSS Builder 1.0</generator>
<ttl>30</ttl>
<item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-26642809</link><guid isPermaLink="false">newstex/PRN-0005-26642809</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> NEW YORK, Jul. ##, #### (PRNewswire delivered by Newstex) -- Kyp Systems, Inc., creator of a patented, paper-based marketing tool called the iKyp(TM), has hired KCSA Strategic Communications as its U.S.-based public relations agency...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04010001</newstex:cat><pubDate>7/14/2008 10:19:13 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001000</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>Kyp Systems Hires KCSA Strategic Communications as U.S. Public Relations Agency of Record</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-26642809</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">AMERICAN EXPRESS CO</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PROCTER &amp; GAMBLE CO</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AXP</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PG</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/spcred/657510</link><guid isPermaLink="false">spcred/657510</guid><spcred:index_mode xmlns:spcred="http://www.alacra.com/spcred">norm</spcred:index_mode><description>The latest Summary from S&amp;P</description><spcred:dataset xmlns:spcred="http://www.alacra.com/spcred">global</spcred:dataset><pubDate>7/2/2008 8:22:39 AM</pubDate><spcred:price xmlns:spcred="http://www.alacra.com/spcred">175</spcred:price><title>Summary: AstraZeneca PLC</title><spcred:type xmlns:spcred="http://www.alacra.com/spcred">Summary</spcred:type><spcred:docid xmlns:spcred="http://www.alacra.com/spcred">657510</spcred:docid><spcred:index_entry_dispcountry xmlns:spcred="http://www.alacra.com/spcred">United Kingdom</spcred:index_entry_dispcountry><spcred:index_entry_dispgics xmlns:spcred="http://www.alacra.com/spcred">Pharmaceuticals</spcred:index_entry_dispgics><spcred:index_entry_dispregion xmlns:spcred="http://www.alacra.com/spcred">Europe, Middle East, Africa</spcred:index_entry_dispregion><spcred:index_entry_dispregion xmlns:spcred="http://www.alacra.com/spcred">United States</spcred:index_entry_dispregion><spcred:index_entry_dispsector xmlns:spcred="http://www.alacra.com/spcred">Global Issuers</spcred:index_entry_dispsector><spcred:index_entry_dispsector xmlns:spcred="http://www.alacra.com/spcred">Corporations</spcred:index_entry_dispsector><spcred:index_entry_dispsector xmlns:spcred="http://www.alacra.com/spcred">Consumer Products</spcred:index_entry_dispsector><spcred:index_entry_dispsector xmlns:spcred="http://www.alacra.com/spcred">Health Care</spcred:index_entry_dispsector><spcred:index_entry_disptype xmlns:spcred="http://www.alacra.com/spcred">Summary</spcred:index_entry_disptype><spcred:index_entry_excerpt xmlns:spcred="http://www.alacra.com/spcred">The ratings on U.K.-based pharmaceuticals company AstraZeneca PLC reflect the group's excellent business profile, underpinned by a blockbuster-rich drug portfolio, superior cash flow generation, and an improving late-stage pipeline. However, its comparatively high product concentration, and exposure to generic competition mitigate these factors. With $29.6 billion in sales and about $10 billion in unadjusted EBITDA in 2007, AstraZeneca continues to be a top-10 player in the global pharmaceuticals market, where critical mass is important in supporting expenditure in research and development (R&amp;D) and marketing activities. We expect the company's strong profitability and superior free cash flow generating ability to continue in 2008, supported by its strong existing drug portfolio including 11 blockbuster drugs in a number of therapeutic areas, each</spcred:index_entry_excerpt><spcred:index_entry_primcountry xmlns:spcred="http://www.alacra.com/spcred">GBR</spcred:index_entry_primcountry><spcred:index_entry_primcusip xmlns:spcred="http://www.alacra.com/spcred">04635R</spcred:index_entry_primcusip><spcred:index_entry_primcusip xmlns:spcred="http://www.alacra.com/spcred">04635P</spcred:index_entry_primcusip><spcred:index_entry_primcusip xmlns:spcred="http://www.alacra.com/spcred">046353</spcred:index_entry_primcusip><spcred:index_entry_primgics xmlns:spcred="http://www.alacra.com/spcred">35202010 352020 3520 35</spcred:index_entry_primgics><spcred:index_entry_primissuer xmlns:spcred="http://www.alacra.com/spcred">AstraZeneca PLC</spcred:index_entry_primissuer><spcred:index_entry_primissuerid xmlns:spcred="http://www.alacra.com/spcred">126474</spcred:index_entry_primissuerid><spcred:index_entry_primreg xmlns:spcred="http://www.alacra.com/spcred">EUROMIDAFR</spcred:index_entry_primreg><spcred:index_entry_primreg xmlns:spcred="http://www.alacra.com/spcred">USA</spcred:index_entry_primreg><spcred:index_entry_primticker xmlns:spcred="http://www.alacra.com/spcred">AZN@LN</spcred:index_entry_primticker><spcred:index_entry_reporttype xmlns:spcred="http://www.alacra.com/spcred">SUMMARY</spcred:index_entry_reporttype><spcred:index_entry_sector xmlns:spcred="http://www.alacra.com/spcred">GLOBISS</spcred:index_entry_sector><spcred:index_entry_sector xmlns:spcred="http://www.alacra.com/spcred">CORP</spcred:index_entry_sector><spcred:index_entry_sector xmlns:spcred="http://www.alacra.com/spcred">Consumer</spcred:index_entry_sector><spcred:index_entry_sector xmlns:spcred="http://www.alacra.com/spcred">Health</spcred:index_entry_sector><category>Credit &amp; Investment Research</category><alacra:ip>S&amp;P Credit Research</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/spcred/657508</link><guid isPermaLink="false">spcred/657508</guid><spcred:index_mode xmlns:spcred="http://www.alacra.com/spcred">norm</spcred:index_mode><description>The latest Full Report from S&amp;P</description><spcred:dataset xmlns:spcred="http://www.alacra.com/spcred">global</spcred:dataset><pubDate>7/2/2008 8:22:00 AM</pubDate><spcred:price xmlns:spcred="http://www.alacra.com/spcred">400</spcred:price><title>AstraZeneca PLC</title><spcred:type xmlns:spcred="http://www.alacra.com/spcred">Full Report</spcred:type><spcred:docid xmlns:spcred="http://www.alacra.com/spcred">657508</spcred:docid><spcred:index_entry_dispcountry xmlns:spcred="http://www.alacra.com/spcred">United Kingdom</spcred:index_entry_dispcountry><spcred:index_entry_dispgics xmlns:spcred="http://www.alacra.com/spcred">Pharmaceuticals</spcred:index_entry_dispgics><spcred:index_entry_dispregion xmlns:spcred="http://www.alacra.com/spcred">Europe, Middle East, Africa</spcred:index_entry_dispregion><spcred:index_entry_dispregion xmlns:spcred="http://www.alacra.com/spcred">United States</spcred:index_entry_dispregion><spcred:index_entry_dispsector xmlns:spcred="http://www.alacra.com/spcred">Global Issuers</spcred:index_entry_dispsector><spcred:index_entry_dispsector xmlns:spcred="http://www.alacra.com/spcred">Corporations</spcred:index_entry_dispsector><spcred:index_entry_dispsector xmlns:spcred="http://www.alacra.com/spcred">Health Care</spcred:index_entry_dispsector><spcred:index_entry_dispsector xmlns:spcred="http://www.alacra.com/spcred">Consumer Products</spcred:index_entry_dispsector><spcred:index_entry_disptype xmlns:spcred="http://www.alacra.com/spcred">Full Report</spcred:index_entry_disptype><spcred:index_entry_excerpt xmlns:spcred="http://www.alacra.com/spcred">Sixth-largest player in the global pharmaceuticals market Strong portfolio of blockbuster drugs Excellent position in lucrative North-American prescription drugs market Superior free cash flow generation Relatively concentrated portfolio of drugs The ratings on U.K.-based pharmaceuticals company AstraZeneca PLC reflect the group's excellent business profile, underpinned by a blockbuster-rich drug portfolio, superior cash flow generation, and an improving late-stage pipeline. However, its comparatively high product concentration, and exposure to generic competition mitigate these factors. With $29.6 billion in sales and about $10 billion in unadjusted EBITDA in 2007, AstraZeneca continues to be a top-10 player in the global pharmaceuticals market, where critical mass is important in supporting expenditure in research and development (R&amp;D) and marketing activities. We expect the company's strong</spcred:index_entry_excerpt><spcred:index_entry_primcountry xmlns:spcred="http://www.alacra.com/spcred">GBR</spcred:index_entry_primcountry><spcred:index_entry_primcusip xmlns:spcred="http://www.alacra.com/spcred">04635R</spcred:index_entry_primcusip><spcred:index_entry_primcusip xmlns:spcred="http://www.alacra.com/spcred">04635P</spcred:index_entry_primcusip><spcred:index_entry_primcusip xmlns:spcred="http://www.alacra.com/spcred">046353</spcred:index_entry_primcusip><spcred:index_entry_primgics xmlns:spcred="http://www.alacra.com/spcred">35202010 352020 3520 35</spcred:index_entry_primgics><spcred:index_entry_primissuer xmlns:spcred="http://www.alacra.com/spcred">AstraZeneca PLC</spcred:index_entry_primissuer><spcred:index_entry_primissuerid xmlns:spcred="http://www.alacra.com/spcred">126474</spcred:index_entry_primissuerid><spcred:index_entry_primreg xmlns:spcred="http://www.alacra.com/spcred">EUROMIDAFR</spcred:index_entry_primreg><spcred:index_entry_primreg xmlns:spcred="http://www.alacra.com/spcred">USA</spcred:index_entry_primreg><spcred:index_entry_primticker xmlns:spcred="http://www.alacra.com/spcred">AZN@LN</spcred:index_entry_primticker><spcred:index_entry_reporttype xmlns:spcred="http://www.alacra.com/spcred">FULL</spcred:index_entry_reporttype><spcred:index_entry_sector xmlns:spcred="http://www.alacra.com/spcred">GLOBISS</spcred:index_entry_sector><spcred:index_entry_sector xmlns:spcred="http://www.alacra.com/spcred">CORP</spcred:index_entry_sector><spcred:index_entry_sector xmlns:spcred="http://www.alacra.com/spcred">Health</spcred:index_entry_sector><spcred:index_entry_sector xmlns:spcred="http://www.alacra.com/spcred">Consumer</spcred:index_entry_sector><category>Credit &amp; Investment Research</category><alacra:ip>S&amp;P Credit Research</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-26378443</link><guid isPermaLink="false">newstex/PRN-0005-26378443</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> WILMINGTON, Del., Jul. #, #### (PRNewswire-FirstCall delivered by Newstex) -- AstraZeneca (NYSE: AZN) today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04006000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04006005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014013</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13001002</newstex:cat><pubDate>7/1/2008 7:15:17 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>Summary Judgment Granted for SEROQUEL(R) Patent Litigation</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-26378443</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">TEVA PHARMACEUTICAL INDUSTRIES LTD</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">TEVA</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/MW-0001-26186187</link><guid isPermaLink="false">newstex/MW-0001-26186187</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> COLOGNE, GERMANY, Jun. ##, #### (Marketwire delivered by Newstex) -- COLOGNE, GERMANY -- (MARKET WIRE) -- ##/##/## --  DIREVO Biotech AG, a world-wide leader in high throughput protein and strain engineering, announced today receipt...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04018000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016031</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002008</newstex:cat><pubDate>6/24/2008 3:17:35 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Marketwire</newstex:Publication><title>DIREVO Receives Broad European Patent Protection for its Protease Optimization Platform</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">MW-0001-26186187</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/HUG-0001-26185195</link><guid isPermaLink="false">newstex/HUG-0001-26185195</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Jun. ##, #### (Hugin AS delivered by Newstex) --   Cologne, Germany, June  ##, ####  - DIREVO Biotech  AG, a  world-wide leader in high throughput  protein and strain engineering,  announced today receipt  of notice  from the  European...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04018000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016031</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002008</newstex:cat><pubDate>6/24/2008 3:17:34 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Hugin AS</newstex:Publication><title>DIREVO Receives Broad European Patent Protection for its Protease  Optimization Platform</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">HUG-0001-26185195</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0002-26183104</link><guid isPermaLink="false">newstex/PRN-0002-26183104</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> SYDNEY, Australia, Jun. ##, #### (Xinhua-PRNewswire-FirstCall delivered by Newstex) -- Pharmaxis (ASX: PXS, Nasdaq: PXSL) today announced the appointment of  senior Australian pharmaceutical executive Will Delaat to its board of directors....</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09015000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>6/23/2008 11:15:34 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18007000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002013</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire Asia</newstex:Publication><title>New Pharmaxis Board Appointment</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0002-26183104</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">MERCK &amp; CO INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">MRK</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-26182981</link><guid isPermaLink="false">newstex/PRN-0005-26182981</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> SYDNEY, Australia, Jun. ##, #### (Xinhua-PRNewswire-FirstCall delivered by Newstex) -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of senior Australian pharmaceutical executive Will Delaat to its board of directors.Mr...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09015000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>6/23/2008 11:15:34 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18007000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002013</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>New Pharmaxis Board Appointment</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-26182981</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">MERCK &amp; CO INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">MRK</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/fitch/424185_pr_frame</link><guid isPermaLink="false">fitch/424185_pr_frame</guid><fitch:index_mode xmlns:fitch="http://www.alacra.com/fitch">html</fitch:index_mode><description>Fitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.</description><fitch:company xmlns:fitch="http://www.alacra.com/fitch">AstraZeneca plc</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Bayer AG</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">GlaxoSmithKline plc</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Novartis AG</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Roche Deutschland Holding GmbH</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Sanofi-Aventis S.A.</fitch:company><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80362434</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457972</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457976</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457979</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457983</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">85884073</fitch:companyid><pubDate>6/18/2008 10:18:00 AM</pubDate><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01000000</fitch:industry><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01030000</fitch:industry><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01031700</fitch:industry><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01031703</fitch:industry><fitch:price xmlns:fitch="http://www.alacra.com/fitch">85</fitch:price><fitch:report xmlns:fitch="http://www.alacra.com/fitch">Press Release</fitch:report><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">AZN</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">BAY</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">GSK</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">NOVN</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">SAN</fitch:ticker><title>Fitch: Sanofi-Aventis' Bid Highlights Interest in Generic Drugs Businesses</title><fitch:docid xmlns:fitch="http://www.alacra.com/fitch">424185_pr_frame</fitch:docid><category>Credit &amp; Investment Research</category><alacra:ip>FitchResearch</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/fitch/423081_pr_frame</link><guid isPermaLink="false">fitch/423081_pr_frame</guid><fitch:index_mode xmlns:fitch="http://www.alacra.com/fitch">html</fitch:index_mode><description>Fitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.</description><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Abbott Laboratories</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">AstraZeneca plc</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Bayer AG</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Fresenius SE</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">GlaxoSmithKline plc</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Merck &amp; Company, Inc.</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Novartis AG</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Pfizer Inc.</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Roche Deutschland Holding GmbH</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Sanofi-Aventis S.A.</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Wyeth</fitch:company><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80091740</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80360516</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80361372</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80361592</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80361630</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80362434</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457972</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457976</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457979</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457983</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">82151338</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">85884073</fitch:companyid><pubDate>6/9/2008 2:13:00 PM</pubDate><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01000000</fitch:industry><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01030000</fitch:industry><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01031700</fitch:industry><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01031703</fitch:industry><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01040000</fitch:industry><fitch:price xmlns:fitch="http://www.alacra.com/fitch">85</fitch:price><fitch:report xmlns:fitch="http://www.alacra.com/fitch">Press Release</fitch:report><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">ABT</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">AZN</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">BAY</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">FRE</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">GSK</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">MRK</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">NOVN</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">PFE</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">SAN</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">WYE</fitch:ticker><title>Fitch Global Pharmaceutical R&amp;D Quarterly: Active 2H of 2008 Expected</title><fitch:docid xmlns:fitch="http://www.alacra.com/fitch">423081_pr_frame</fitch:docid><category>Credit &amp; Investment Research</category><alacra:ip>FitchResearch</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/fitch/388942_report_frame</link><guid isPermaLink="false">fitch/388942_report_frame</guid><fitch:index_mode xmlns:fitch="http://www.alacra.com/fitch">pdf</fitch:index_mode><description>Fitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.</description><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Abbott Laboratories</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Amgen, Inc.</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">AstraZeneca plc</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Bristol-Myers Squibb Company</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Eli Lilly &amp; Company</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">GlaxoSmithKline plc</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Johnson &amp; Johnson</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Merck &amp; Company, Inc.</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Novartis AG</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Pfizer Inc.</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Roche Deutschland Holding GmbH</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Sanofi-Aventis S.A.</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Schering-Plough Corporation</fitch:company><fitch:company xmlns:fitch="http://www.alacra.com/fitch">Wyeth</fitch:company><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80091740</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80360516</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80361372</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80361419</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80361592</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80361630</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80362434</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80417179</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457972</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457976</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457979</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80457983</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80656236</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80710410</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">80843884</fitch:companyid><fitch:companyid xmlns:fitch="http://www.alacra.com/fitch">85094473</fitch:companyid><pubDate>6/9/2008 10:11:00 AM</pubDate><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01000000</fitch:industry><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01030000</fitch:industry><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01031700</fitch:industry><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01031703</fitch:industry><fitch:industry xmlns:fitch="http://www.alacra.com/fitch">01040000</fitch:industry><fitch:price xmlns:fitch="http://www.alacra.com/fitch">275</fitch:price><fitch:report xmlns:fitch="http://www.alacra.com/fitch">Special Report</fitch:report><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">ABT</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">AMGN</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">AZN</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">BMY</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">GSK</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">JNJ</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">LLY</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">MRK</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">NOVN</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">PFE</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">SAN</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">SGP</fitch:ticker><fitch:ticker xmlns:fitch="http://www.alacra.com/fitch">WYE</fitch:ticker><title>Global Pharmaceutical R&amp;D Pipeline (First-Quarter 2008)</title><fitch:docid xmlns:fitch="http://www.alacra.com/fitch">388942_report_frame</fitch:docid><category>Credit &amp; Investment Research</category><alacra:ip>FitchResearch</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-25565600</link><guid isPermaLink="false">newstex/PRN-0005-25565600</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> MONTVALE, N.J., May ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by AstraZeneca...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016031</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>5/27/2008 5:17:08 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18020000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001000</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>Barr Confirms Patent Challenge of Entocort(R), 3mg Enteric Coated Capsules</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-25565600</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">BARR PHARMACEUTICALS INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">BRL</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0001-25311461</link><guid isPermaLink="false">newstex/PRN-0001-25311461</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> &lt;&lt;     -   FDA appeal progressing     -   Appointment of new board of director     -   PREPARE data selected as a 'highlighted' poster at American Heart         Association Conference on Arteriosclerosis, Thrombosis and Vascular   ...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07013000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016047</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016003</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016013</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04009000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04009002</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><pubDate>5/15/2008 5:18:38 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18020000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18004000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18022000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18010000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18015000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002012</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Canada NewsWire Group</newstex:Publication><title>PreMD Reports First Quarter Results</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0001-25311461</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">MEDCOMSOFT INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PREMD INC.</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">MSF</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PMD</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/HUG-0001-25123690</link><guid isPermaLink="false">newstex/HUG-0001-25123690</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> May #, #### (Hugin AS delivered by Newstex) -- Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016048</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016018</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13001002</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>5/8/2008 12:17:29 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18008000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18004000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18012000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18020000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Hugin AS</newstex:Publication><title>Micromet, Inc. Reports First Quarter 2008 Financial Results</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">HUG-0001-25123690</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">MERCK &amp; CO INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">MICROMET INC.</newstex:index_entry_company><newstex:index_entry_person xmlns:newstex="http://www.alacra.com/newstex">Christian NULL Itin</newstex:index_entry_person><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">MITI</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">MRK</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-25057365</link><guid isPermaLink="false">newstex/BW-0001-25057365</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> WINSTON-SALEM, N.C., May #, #### (Business Wire) -- Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today reported its financial results for the...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">11000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">11002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016048</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016018</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014019</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014013</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001006</newstex:cat><pubDate>5/6/2008 5:19:18 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18008000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18004000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18020000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><title>Targacept Reports First Quarter 2008 Financial Results</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-25057365</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">TARGACEPT INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">TRGT</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-24868386</link><guid isPermaLink="false">newstex/PRN-0005-24868386</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> GOTHENBURG, Sweden, April ##, Apr. ##, #### (PR Newswire delivered by Newstex) --  GOTHENBURG, Sweden, April ## /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery, announced today that its board...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><pubDate>4/29/2008 11:18:48 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18007000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>Jonas Ohlsson Appointed CEO/President of Cellectricon</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-24868386</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">APPLERA CORP</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">ABI</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">CRA</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0001-24869155</link><guid isPermaLink="false">newstex/PRN-0001-24869155</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Apr. ##, #### (Canada NewsWire Group delivered by Newstex) -- GOTHENBURG, Sweden, April ## /CNW/ - Cellectricon, a leading provider of screening solutions for drug discovery, announced today that its board of directors has appointed...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><pubDate>4/29/2008 11:18:44 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18007000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Canada NewsWire Group</newstex:Publication><title>Jonas Ohlsson Appointed CEO/President of Cellectricon</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0001-24869155</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">APPLERA CORP</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">ABI</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">CRA</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0003-24861179</link><guid isPermaLink="false">newstex/PRN-0003-24861179</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> GOTHENBURG, Sweden, Apr. ##, #### (PR Newswire Europe delivered by Newstex) -- Cellectricon, a leading provider of screening solutions for drug discovery, announced today that its board of directors has appointed Jonas Ohlsson as the...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><pubDate>4/29/2008 4:14:35 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18007000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire Europe</newstex:Publication><title>Jonas Ohlsson Appointed CEO/President of Cellectricon</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0003-24861179</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">APPLERA CORP</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">ABI</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">CRA</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/HUG-0001-24859227</link><guid isPermaLink="false">newstex/HUG-0001-24859227</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Apr. ##, #### (Hugin AS delivered by Newstex) -- This is Enfo's Interim Report without tables section. The full Interim Report with tables attached and at www.enfo.fi. A The reference figures from #### are based on comparable figures...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09015000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016002</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04003005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04006000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04006012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04009000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04009003</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002006</newstex:cat><pubDate>4/29/2008 3:19:09 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18016000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18022000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19003000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002014</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002018</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002006</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Hugin AS</newstex:Publication><title>Enfo Oyj's interim report 1 January - 31 March 2008</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">HUG-0001-24859227</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ARI NETWORK SERVICES INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">ARIS</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-24788560</link><guid isPermaLink="false">newstex/BW-0001-24788560</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> CHAPEL HILL, N.C., Apr. ##, #### (Business Wire) -- POZEN Inc. (NASDAQ: POZN), announced today that it will release first quarter #### results on May #, ####, before the market opens.     The announcement will be followed by a live...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016048</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016018</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><pubDate>4/25/2008 11:15:14 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18008000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18004000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><title>POZEN Announces May 8, 2008 Webcast of First Quarter 2008 Results</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-24788560</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">POZEN INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">POZN</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item></channel></rss>